E

SABCS25 Highlights – Reading between the slides

Review of 10 key early and late stage trials, including Relay and Scorpion's mutant selective PI3Kα inhibitors

December 17, 2025
E

Building an ADC platform beyond the Topo-I crowd

The hunt for novel payloads for ADCs continues apace

November 17, 2025
E

SITC25: Findings Worth Your Attention

SITC25 Roundup with some suprising findings to take note of

November 10, 2025
E

A new KRAS G12D inhibitor finds its footing

Targeting KRAS G12D has already seen some shakeout – can the next generation agents prove successful?

October 28, 2025
E

CrossBridge Bio and Chengdu Kanghong ratchet up the stakes

A look at emerging ADCs in many shapes and flavours, including dual and novel payload versions

October 24, 2025
E

A bear thesis – why HARMONi-6 won’t replicate globally

The trouble with translating Chinese trials to Western populations

October 22, 2025
E

Revenge of the Farnesyltransferase Inhibitors

A classic comeback story

October 20, 2025
E

Another brick in the wall

New developments in metastatic and early stage breast cancer from Berlin

October 18, 2025
E

Beyond the Biergarten: ESMO’s Unusually Productive Friday

Highlights and lowlights from Day 1 of ESMO25

October 17, 2025
E

The next generation of cancer therapeutics at ESMO

A look at some early stage IO agents and small molecules coming down the pike

October 14, 2025
E

Purple Cows at ESMO: six ADC trends worth watching

Standing out from the crowd – 6 ADC trends to watch out for at ESMO

October 9, 2025